{{Infobox company
| name   = C. H. Boehringer Sohn AG & Co. KG
| logo   = Bilogo new.jpg
| type   = [[Private company|Private]]
| slogan   = Value through Innovation
| foundation       = [[Ingelheim am Rhein]], Germany ({{Start date|1885}})
| location_city    = <!--Binger Str. 173, 55216-->[[Ingelheim]]
| location_country = Germany
| area_served      = Worldwide
| key_people     = {{unbulleted list|Hubertus von Baumbach, [[Chairman]] of the board,|Simone Menne, board member|Allan Hillgrove, board member|Joachim Hasenmaier, board member|Andreas Neumann, board member |Michel Pairet, board member}}
| industry = [[Pharmaceuticals]]
| num_employees  = 50.000~ 
| products       = Human Pharmaceuticals and Animal Health
| revenue        = {{profit}} €15.9 billion (2016)<ref name="uk.reuters.com">{{cite web|url=http://uk.reuters.com/article/uk-boehringer-results-idUKKBN1770VG|title=Boehringer eyes marked sales gain, boosted by animal health|first=Reuters|last=Editorial|publisher=}}</ref>
| operating_income = {{profit}} €2.9 billion (2016)<ref name="uk.reuters.com"/>
| IAT            = {{profit}} €1.2 billion (2014)
| assets         = {{profit}} €20.05 billion (2014)
| equity         = {{profit}} €8.111 billion (2014)
| homepage       = {{url|www.boehringer-ingelheim.com}}
}}

'''C.H. Boehringer Sohn AG & Ko. KG''' is the parent company of '''Boehringer Ingelheim GmbH''', which was founded in 1885 by Albert Boehringer in [[Ingelheim am Rhein]], Germany. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Still headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. The company's key areas of interest are: [[respiratory diseases]], [[metabolism]], [[immunology]], [[oncology]] and diseases of the [[central nervous system]]. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations [[EFPIA]]. The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of [[Charlemagne]].<ref>{{cite web | title=Boehringer Ingelheim Logo | url=http://www.famouslogos.us/boehringer-ingelheim-logo | website=Famous Logos | accessdate=18 August 2011 }}</ref>

==Activities==
Boehringer Ingelheim works in human [[pharmaceutical]]s, [[animal health]] and [[biopharmaceutical]]s. The group consists of 145 affiliated companies with 50.000~ employees in 2017 in all continents. [[Research and development]] facilities were in five sites and 20 production plants in 13 countries. The research and development facilities are located in [[Biberach an der Riss|Biberach]] (Germany), [[Ridgefield, Connecticut|Ridgefield]] (Connecticut), [[Vienna]], [[Kobe]], and [[Milan]](closed in 2017). Over 8,000 employees work for Boehringer Ingelheim in research and development.

==Company history==
In 2004 the company acquired STEAG microParts GmbH.<ref>{{cite web|url=http://www.analytica-world.com/en/news/39610/boehringer-ingelheim-to-acquire-steag-microparts-gmbh.html|title=Boehringer Ingelheim to acquire STEAG microParts GmbH|website=www.analytica-world.com}}</ref> In December of the same year the company announced the acquisition of the outstanding shares of  Boehringer Ingelheim Shionogi Vetmedica.<ref>{{cite web|url=http://www.mynewsdesk.com/se/boehringer_ingelheim_ab/pressreleases/boehringer-ingelheim-announces-acquisition-of-the-remaining-shares-in-boehringer-ingelheim-shionogi-vetmedica-bisv-82737?view_policy=1|title=Boehringer Ingelheim Announces Acquisition of the Remaining Shares in Boehringer Ingelheim Shionogi Vetmedica (BISV)|publisher=}}</ref>

In June 2008, the company announced its intention to acquire [[Actimis Pharmaceuticals]] for $515 million, depending on the performance of Actimis' leading asthma compound AP768.<ref>http://www.actimis.com/actimisBI6172008.pdf</ref>

In 2009 through its US subsidiary, Boehringer Ingelheim Vetmedica Inc., acquired a significant portion of the Fort Dodge Animal Health business from [[Pfizer]].<ref>http://www.thehorse.com/articles/24437/boehringer-ingelheim-to-acquire-some-fort-dodge-equine-products</ref>

In 2010 BI, through its Boehringer Ingelheim Japan Investment GK subsidiary, acquired all outstanding shares of SSP CO., Ltd, with Nippon Boehringer Ingelheim Co., Ltd already holding 60.2% of SSP CO's shares.<ref>{{cite web|url=https://www.pharmpro.com/news/2010/02/boehringer-ingelheim-announces-its-intention-acquire-all-outstanding-shares-ssp-co-ltd|title=Boehringer Ingelheim announces its intention to acquire all the outstanding shares in SSP Co., Ltd. ("SSP") through a tender offer|date=18 February 2010|publisher=}}</ref>

In August 2012 the company acquired [[FX125L]] and the [[somatotaxin]] programme from Funxional Therapeutics for an undisclosed sum.<ref>{{cite web|url=https://www.enterprise.cam.ac.uk/news/boehringer-ingelheim-and-funxional-therapeutics-announce-acquisition-of-funxionals-fx125l-and-the-somatotaxin-portfolio-to-treat-inflammation/|title=Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional’s FX125L - Cambridge Enterprise|first=Who made this|last=site.|publisher=}}</ref>

In May 2015, the company acquired the investigational drug PXS4728A from [[Pharmaxis]]’.<ref>{{cite web|url=https://www.europeanpharmaceuticalreview.com/news/31663/boehringer-ingelheim-acquires-pharmaxis-investigational-drug-pxs4728a/|title=Boehringer Ingelheim acquires Pharmaxis' PXS4728A|website=www.europeanpharmaceuticalreview.com}}</ref> In July, the company sold its [[Roxane Laboratories|Roxane]] business to [[Hikma Pharmaceuticals|Hikma Pharmaceuticals Plc]] for $2.65 billion  ($1.18 billion in cash and issue 40 million new Hikma shares). The company also agreed to make cash payments of up to $125 million based on performance milestones.<ref>{{cite news| url=https://www.bloomberg.com/news/articles/2015-07-28/hikma-to-buy-roxane-from-boehringer-ingelheim-for-2-65-billion | work=Bloomberg | first=Marthe | last=Fourcade | title=Hikma to Buy Boehringer Ingelheim's Roxane for $2.65 Billion | date=28 July 2015}}</ref><ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/hikma-buys-roxane-for-2-65b-expanding-u-s-generics-presence/81251562/|title=Hikma Buys Roxane for $2.65B, Expanding U.S. Generics Presence - GEN News Highlights - GEN|publisher=}}</ref> On the same day the company announced it would partner with [[Hanmi Pharmaceutical]] to develop and commercialise [[HM61713]], a third generation treatment for [[Epidermal growth factor receptor|EGFR]] mutation-positive [[lung cancer]].<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/boehringer-licenses-hanmi-lung-cancer-drug-for-up-to-730m/81251557/|title=Boehringer Licenses Hanmi Lung Cancer Drug for Up-to $730M+ - GEN News Highlights - GEN|publisher=}}</ref> Boehringer also terminated its collaboration with Vitae Pharmaceuticals on a new [[BACE]] program for Alzheimer's.<ref>{{cite web|url=http://www.fiercebiotech.com/story/boehringer-dumps-its-alzheimers-bace-pact-vitae/2015-07-27|title=Boehringer dumps its Alzheimer's BACE pact with Vitae - FierceBiotech|publisher=}}</ref>

The company sold the rights to [[Faldaprevir]], a HCV protease inhibitor to Trek Therapeutics.<ref>{{cite web|url=http://trektx.com/portfolio/|title=Portfolio - Trek Therapeutics|publisher=}}</ref>

In July 2016 the company sold the commercialisation rights to [[BI 655066]], to AbbVie for $595 million upfront as well as undisclosed milestone payments and royalties. BI 655066 is a drug in late-stage testing for [[psoriasis]], and in earlier testing for [[Crohn's disease]], [[psoriatic arthritis]] and [[asthma]].<ref>{{cite web|url=http://www.investors.com/news/technology/abbvie-bolster-immunology-business-with-boehringer-drug-buy/|title=AbbVie Bolsters Immunology Business, Acquires Boehringer Drug - Stock News & Stock Market Analysis - IBD|first=Investor's Business|last=Daily|website=www.investors.com}}</ref> In September of the same year the company announced it would acquire [[ViraTherapeutics]] for €210 million ($230 million<ref>{{cite web|url=http://www.biospace.com/News/boehringer-ingelheim-bets-230-million-on-newcomer/433920|title=Boehringer Ingelheim Bets 230 Million on Newcomer ViraTherapeuticss Immune Oncology Pipeline|website=www.biospace.com}}</ref>), a developer of oncolytic virus therapies, dependant on the success of Phase I trials.<ref>{{cite web|url=http://labiotech.eu/boehringer-e210m-virus-immuno-oncology/|title=Boehringer offers €210M to get into Virus-based Immuno-Oncology|date=29 September 2016|publisher=}}</ref><ref>{{cite web|url=http://www.fiercebiotech.com/biotech/boehringer-nabs-up-to-eu210m-oncolytic-virus-option-deal-austrian-startup|title=Boehringer nabs up to €210M oncolytic virus option deal with Austrian startup - FierceBiotech|website=www.fiercebiotech.com}}</ref>

===2016 – Sanofi asset swap===
{{see also|Sanofi|Merial}}
In June 2016, the company announced it had struck an asset-swap deal with [[Sanofi]], Boehringer would sell its consumer health division (valuing it at €6.7 billion) and €4.7 billion in cash, whilst acquiring the [[Merial]] animal health division (valuing it at €11.4 billion / $12.4 billion). The deal could mean that Boehringer is now one of the animal healthcare global leaders.<ref>{{cite web|url=http://www.fiercepharma.com/pharma/aiming-for-top-dog-status-sanofi-and-boehringer-swap-animal-and-consumer-health-units|title=Aiming for top dog status, Sanofi and Boehringer swap animal and consumer health units - FiercePharma|publisher=}}</ref> In September of the same year, [[Amgen]] announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound ([[BI 836909]], now AMG 420) for use in the treatment of [[multiple myeloma]].<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/amgen-buys-rights-to-myeloma-bite-immunotherapy-from-boehringer-ingelheim/81253166/|title=Amgen Buys Rights to Myeloma BiTE Immunotherapy from Boehringer Ingelheim - GEN News Highlights - GEN|publisher=}}</ref> As part of the asset swap, Boehringer and Merial sold a number of assets to [[Ceva Santé Animale]] - namely some animal health vaccines and pharmaceuticals from the Merial portfolio for swine, bovine and companion animals, as well as some intellectual property, manufacturing processes and R&D activities.<ref>{{cite web|url=https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-announces-agreement-ceva-sant-animale-sale-certain-merial-assets|title=Boehringer Ingelheim announces agreement with Ceva Santé Animale for the sale of certain Merial assets|website=boehringer-ingelheim.com}}</ref><ref>{{cite web|url=https://www.ftc.gov/news-events/press-releases/2016/12/ftc-requires-divestitures-condition-proposed-1353-billion-deal|title=FTC Requires Divestitures as Condition to Proposed $13.53 Billion Deal between German Pharmaceutical Boehringer Ingelheim and Paris-based Sanofi|date=28 December 2016|publisher=}}</ref> In October 2016 the company sold its US pet vaccines business and a manufacturing plant for $885 million, to [[Eli Lilly Co]]s [[Elanco|Elanco Animal Health]] division.<ref>{{cite web|url=http://www.domain-b.com/companies/companies_e/Eli_Lilly/20161005_business.html|title=domain-b.com : Eli Lilly to buy Boehringer Ingelheim's US pet vaccines business for $885 mn|website=www.domain-b.com}}</ref><ref>{{cite web|url=http://www.finanzen.net/nachricht/aktien/elanco-animal-health-enters-agreement-to-acquire-boehringer-ingelheim-vetmedica-s-u-s-feline-canine-and-rabies-vaccines-portfolio-5117818|title=Elanco Animal Health Enters Agreement to Acquire Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio|publisher=}}</ref>

===Timeline===
*'''1885''': Albert Boehringer buys a small tartar factory in Ingelheim am Rhein; work begins on 1 August.{{Citation needed|date=October 2012}}
*'''1886''': The factory commences production of [[tartaric acid]] for use in the food industry (e.g. in [[baking powder]] and carbonated beverages).
*'''1893''': Albert Boehringer renames the company C. H. Boehringer Sohn (CHBS) after his father, Christoph Heinrich Boehringer.{{Citation needed|date=October 2012}}
*'''1893''': While experimenting with the production of citric acid, lactic acid is formed. Albert Boehringer develops this process, with the intention of producing lactic acid on a larger scale.
*'''1895''': Lactic acid is produced on an industrial scale, and is successful commercially.
*'''1917''': Professor Heinrich Wieland, chemist, future [[Nobel Prize]] winner and cousin of Albert Boehringer, sets up the company’s research department.
*'''1928''': Albert Boehringer purchases Dr. Karl Thomae, a company based in Winnenden near Stuttgart.{{Citation needed|date=October 2012}}
*'''1946''': Dr. Karl Thomae GmbH is re-opened in Biberach an der Riss with a staff of 70 people.
*'''1954''': The company hires former Nazi [[Fritz Fischer (medical doctor)|Fritz Fischer]] after he is released from jail. Fischer was convicted of [[war crime]]s and [[crimes against humanity]] at the [[Nuremberg Trials]].
*'''1955''': The Animal Health division is established as the company acquires Pfizer’s veterinary programme.
*'''1971''': The foreign subsidiary, Boehringer Ingelheim Pharmaceuticals, Inc is founded in Ridgefield, Connecticut (USA). This site is soon expanded, and becomes the company’s North American research centre.
*'''1985''': The Institute for Molecular Pathology (IMP) is established in Vienna; it opens in 1988. 
*'''1986''': The biotechnological centre in Biberach begins production of [[biopharmaceuticals]] from cell cultures.{{Citation needed|date=October 2012}} 
*'''1998''': The merging of Boehringer Ingelheim KG and Dr. Karl Thomae GmbH founds Boehringer Ingelheim Pharma KG.

===Collaborative research===
Boehringer Ingelheim is involved in publicly funded collaborative research projects with other industrial and academic partners. One example in the area of [[Pre-clinical development|non-clinical]] safety assessment is the [[Toxicogenomics#InnoMed PredTox|InnoMed PredTox]].<ref>{{Cite book| last1 = Mattes | first1 = William B.| chapter = Public Consortium Efforts in Toxicogenomics | doi = 10.1007/978-1-60327-048-9_11 | title = Essential Concepts in Toxicogenomics| editor1-last = Mendrick | editor1-first = Donna L.| editor2-last = Mattes | editor2-first = William B.| series = [[Methods in Molecular Biology]]| volume = 460 | pages = 221–238 | year = 2008 | isbn = 978-1-58829-638-2 | pmid = 18449490 | pmc = }}</ref><ref name="InnoMed PredTox official project website">{{cite web | url=https://www.genedata.com/index.php?id=515consortium/members/ | archive-url=https://archive.is/20121204181603/http://www.genedata.com/index.php?id=515consortium/members/ | archive-date=4 December 2012 | deadurl=no<!--excluded from archive.org--> | title=InnoMed PredTox | at=InnoMed PredTox Members | accessdate=28 November 2014 | publisher=[[Genedata]] }}</ref>  The company is expanding its activities in joint research projects within the framework of the [[Innovative Medicines Initiative]] of [[EFPIA]] and the [[European Commission]].<ref name="IMI Call Topics 2008">{{cite web|url=http://www.eurosfaire.prd.fr/7pc/documents/1210683220_imi_1rst_call_topics.pdf | format=PDF | title=IMI Call Topics 2008 | author=Innovative Medicines Initiative | authorlink=Innovative Medicines Initiative | website=EUROSFAIRE | publisher=[[Ministry of Higher Education and Research]] | location=France | accessdate=2008-08-25 }}</ref>

==Operational/development sites==
Boehringer Ingelheim is a globally operating company, with 146 subsidiaries around the globe. The company's largest site and corporate headquarters is in Ingelheim am Rhein near Mainz and Frankfurt, Germany. Their main business regions are Europe, North America and Asia.  The Research Institute of Molecular Pathology[5] in Vienna (Austria), founded in 1985, has had Boehringer Ingelheim as its main sponsor since 1993.{{Citation needed|date=October 2012}}  The company's [[Generic drug#Economics|generic pharmaceutical business]] is vested in the [[Ohio]], United States-based Roxane Labs subsidiary.<ref>{{cite news | title=Boehringer May Sell U.S. Generics Unit | agency=[[Bloomberg L.P.|Bloomberg]] | date=15 January 2015 | url=http://www.pharmamanufacturing.com/industrynews/2015/boehringer-may-sell-u-s-generics-unit/ | author=Staff | work=Pharmaceutical Manufacturing | publisher=Putman Media }}</ref>

==Closure of drug manufacturing plant==
In 2011 Ben Venue Laboratories in [[Bedford, Ohio]], a division of Boehringer Ingelheim, voluntarily shut down after a [[U.S. Food and Drug Administration]] inspectors' report that found the plant had rusty tools, mold, and a barrel of 'unknown liquid', later found to be [[urine]].<ref name=FDA>{{cite web | title=Ben Venue Laboratories – Voluntary Shutdown | url=http://www.fda.gov/Drugs/DrugSafety/ucm281782.htm | website=Drug Safety and Availability | publisher=[[USFDA]] | accessdate=18 October 2012 | date=30 November 2011<!--last updated--> }}</ref><ref name="NYT Oct 18 2012">{{cite news | last=Thomas | first=Katie | title=Lapses at Big Drug Factories Add to Shortages and Danger | url=https://www.nytimes.com/2012/10/18/business/drug-makers-stalled-in-a-cycle-of-quality-lapses-and-shortages.html | work=[[The New York Times]] | date=18 October 2012<!--print edition--> | page=A1 }}</ref>  The company invested {{currency|300 million}} to upgrade the drug manufacturing plant, and limited production resumed in October 2012.<ref name="NYT Oct 18 2012"/>  However, on 3 October 2013, Ben Venue announced that it would be ceasing production by the end of 2013 due to being unable to "return to sustainable production."<ref name=BVL>{{cite press release | title=Ben Venue Laboratories, Inc to Cease Production | date=3 October 2013 | url=http://www.benvenue.com/news_/press_releases/october_3_2013.html | publisher=Ben Venu Laboratories | deadurl=yes | archivedate=4 October 2013 | archiveurl=https://web.archive.org/web/20131004220320/http://www.benvenue.com/news_/press_releases/october_3_2013.html }}</ref>

==Key product lines==

'''Prescription Medicine:'''
* [[Actilyse]] ([[alteplase]])
* Aggrenox ([[dipyridamole]] / [[acetylsalicylic acid]])
* Alna / [[Flomax]] ([[tamsulosin]]) 
* Aptivus ([[tipranavir]])
* Berodual ([[ipratropium bromide]] / [[fenoterol]])
* Combivent ([[ipratropium bromide / salbutamol]]) 
* Gilotrif / Giotrif ([[afatinib]])
* Jardiance ([[empagliflozin]])
* Jentadueto / TrajentaDuo ([[linagliptin]] / [[metformin]])
* [[Metalyse]] ([[tenecteplase]])
* Micardis ([[telmisartan]]) 
* Micardis Plus / Micardis HCT ([[telmisartan / hydrochlorothiazide]]) 
* Mirapex / Sifrol ([[pramipexole]])
* [[Mobic]] / [[Movalis]] ([[meloxicam]]) 
* Pradaxa ([[dabigatran|dabigatran etexilate]]) 
* [[Spiriva]] ([[tiotropium bromide]])
* Trajenta / Tradjenta ([[linagliptin]])
* [[Twynsta]] (telmisartan / [[amlodipine]]) 
* Viramune ([[nevirapine]])

'''Consumer Health Care:'''
* Antistax (red vine leaf extract)
* [[Bisolvon]] ([[bromhexine]])
* [[Buscopan]] / [[Buscapina]] ([[hyoscine hydrobromide|hyoscine butylbromide]]) 
* [[Bisacodyl|Dulcolax]] ([[bisacodyl]])
* [[Zantac]] ([[ranitidine]])—75 and 150&nbsp;mg tablets; 300&nbsp;mg tablets, syrup and solution for injection are manufactured by [[GlaxoSmithKline]]
* Mucoangin / Mucosolvan ([[ambroxol]])
* [[Pharmaton]] (standardized ginseng extract, vitamins, minerals, trace elements) 
* [[Silomat]] ([[dextromethorphan]]) 
* Thomapyrin ([[acetylsalicylic acid]], [[paracetamol]], [[caffeine]])

'''Animal Health:''' 
* [[CircoFLEX]] ([[porcine circovirus]] vaccine type 2, killed ''Baculovirus'' vector)
* [[Duramune]] (a line of pet vaccines) 
* [[Metacam]] ([[meloxicam]])
* [[MycoFLEX]] (''[[Mycoplasma hyopneumoniae]]'' bacterin)
* [[Vetmedin]] ([[pimobendan]])
* [[Pexion]] ([[imepitoin]])

==Product pipeline==
Boehringer Ingelheim's product pipeline targets [[lung disease]], [[cancer]], and [[hepatitis C]].<ref name=pipeline>{{cite web | title=Pipeline | publisher=Boehringer Ingelheim | url=http://www.boehringer-ingelheim.com/research_development/drug_discovery/pipeline.html | accessdate=12 September 2013 }}</ref>
{| class="wikitable sortable" style="text-align:center";
|-valign="bottom"
! width="20%"|Drug Name
! width="30%"|Description
! width="30%"|Potential Indication
! width="20%"|Testing Phase
|-valign="top"
|'''[[Olodaterol]]'''
|[[Long-acting beta-agonist]]
|[[Chronic obstructive pulmonary disease]] (COPD)
|Approved
|-valign="top"
|'''[[Tiotropium]]'''
|Long acting muscarinic antagonist
|[[Cystic fibrosis]] (CF) / [[asthma]]. Already approved for [[chronic obstructive pulmonary disease]] (COPD)
|Approved
|-valign="top"
|'''[[Nintedanib]]'''
|Triple angiokinase inhibitor, simultaneously blocks [[VEGFR]], [[FGFR]], [[PDGFR]]
|[[Idiopathic pulmonary fibrosis]] (IPF) / [[non-small cell lung cancer]] (NSCLC) / [[ovarian cancer]]
|Phase III
|-valign="top"
|'''[[Afatinib]]'''
|Irreversible [[ErbB]] family blocker
|[[Breast cancer]] / [[head and neck cancer]]. Already approved for [[non-small cell lung cancer]] (NSCLC)
|Phase III
|-valign="top"
|'''[[Volasertib]]'''
|[[PLK1]] antagonist
|Various cancer types
|Phase III
|-valign="top"
|'''[[Deleobuvir]] (formerly BI 207127)'''
|[[NS5B]] RNA-dependent polymerase inhibitor
|[[Hepatitis C]]
|Phase III
|-valign="top"
|'''[[Faldaprevir]] (formerly BI 201335)'''
|[[NS3 (HCV)|NS3]]/[[NS4A|4A]] protease inhibitor
|[[Hepatitis C]]
|Phase III
|-valign="top"
|'''[[Empagliflozin]]'''
|[[SGLT-2]]-inhibitor
|[[Diabetes mellitus type II]]
|Approved<ref>{{cite web|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407637.htm|title=Press Announcements - FDA approves Jardiance to treat type 2 diabetes|publisher=}}</ref>
|-valign="top"
|'''[[Idarucizumab]]'''
|Humanized antibody fragment (FAB), specific reversal agent to [[dabigatran]]
|Reversal of dabigatran-induced [[anticoagulation]] in case of an emergency
|Phase III
|}

===Litigation===
In October 2012 Boehringer Ingelheim settled a "qui tam" (whistleblower) case with the U.S. government for $95 million alleging "off-label" marketing of the drugs Aggrenox, Atrovent, Combivent, and Micardis for uses that weren't approved by the US Food and Drug Administration and were not covered by federal health care programs.<ref>{{cite press release | url=http://www.phillipsandcohen.com/2012/Boehringer-Ingelheim-pays-95-million-to-settle-whistleblower-case.shtml | title=Boehringer Ingelheim pays $95 million to settle whistleblower case | publisher=Phillips & Cohen | date=25 October 2012 }}</ref>

In August 2012, Pradaxa claims filed in the federal court were consolidated in a multi-district litigation in the Southern District of Illinois before Chief Judge David R. Herndon. On 28 May 2014, a $650 million settlement was announced on behalf of approximately 3,900 claimants who were injured by the drug Pradaxa made by Boehringer Ingelheim Pharmaceuticals, Inc. The drug is alleged to cause severe bleeding events and/or hemorrhaging to those who were taking the drug.<ref name="thomas2014">{{cite news | title=$650 Million to Settle Blood Thinner Lawsuits | author=Thomas, Katie | url=https://www.nytimes.com/2014/05/29/business/international/german-drug-company-to-pay-650-million-to-settle-blood-thinner-lawsuits.html | work=[[The New York Times]] | date=28 May 2014 }}</ref>

==In popular culture==
The Company is mentioned as being a former place of work for one of the Characters in Season Two, Episode Ten, of the Scandinavian Police thriller Series, [[The Bridge (Danish/Swedish TV series)|''The Bridge'' (Danish/Swedish TV series)]].

==See also==
*[[Robert Boehringer]]

==References==

{{Reflist|33em}}

==External links==
*[http://www.boehringer-ingelheim.com Boehringer Ingelheim Corporate website]

[[Category:Biotechnology companies of Germany]]
[[Category:Multinational companies]]
[[Category:Companies based in Rhineland-Palatinate]]
[[Category:German brands]]
[[Category:Pharmaceutical companies of Germany]]
[[Category:Chemical companies of Germany]]
[[Category:Pharmaceutical companies established in 1885]]
[[Category:1885 establishments in Germany]]
[[Category:Medical and health organisations based in Rhineland-Palatinate]]